<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-041319</identifier>
<setSpec>0014-2565</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Clinical efficacy of ezetimibe and combined use with statins</dc:title>
<dc:description xml:lang="en">The use of statins is very extensive in patients with some previous cardiovascular complication. However, the new therapeutic objectives of LDL-C, especially in high risk patients, makes it difficult to reach the LDL-C values desired in the daily clinical practice. The appearance of a new inhibitor of the intestinal cholesterol absorption (ezetimibe) noticeably strengthens the actions of the statins in the reduction of LDL-C. Combined use of ezetimibe and statins may make it possible for the vascular high risk patients to reach a greater reduction of LDL-C and achieve the therapeutic objectives more frequentlyThe use of statins is very extensive in patients with some previous cardiovascular complication. However, the new therapeutic objectives of LDL-C, especially in high risk patients, makes it difficult to reach the LDL-C values desired in the daily clinical practice. The appearance of a new inhibitor of the intestinal cholesterol absorption (ezetimibe) noticeably strengthens the actions of the statins in the reduction of LDL-C. Combined use of ezetimibe and statins may make it possible for the vascular high risk patients to reach a greater reduction of LDL-C and achieve the therapeutic objectives more frequently</dc:description>
<dc:creator>Sánchez Juan, C</dc:creator>
<dc:creator>Pascual Izuel, J. M</dc:creator>
<dc:creator>Rodilla Sala, E</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">El uso de estatinas es muy amplio en las pacientes con alguna complicación cardiovascular previa. Sin embargo, los nuevos objetivos terapéuticos de colesterol ligado a lipoproteínas de baja densidad (c-LDL), especialmente en pacientes de alto riesgo, hacen que sea difícil alcanzar los valores de c-LDL deseados en la práctica clínica diaria. La aparición de un nuevo inhibidor de la absorción del colesterol intestinal (ezetimiba) potencia notablemente la acción de las estatinas en la reducción del c-LDL. El uso combinado de ezetimiba y estatinas puede permitir a los pacientes de alto riesgo vascular alcanzar una mayor reducción del c-LDL y conseguir con mayor frecuencia los objetivos terapéuticos</dc:description>
<dc:source>Rev Clin Esp;205(10): 496-498, oct. 2005.</dc:source>
<dc:identifier>ibc-041319</dc:identifier>
<dc:title xml:lang="es">Eficacia clínica de la ezetimiba y uso combinado con estatinas</dc:title>
<dc:subject>^d28612</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d931^s22079</dc:subject>
<dc:subject>^d7117^s22057</dc:subject>
<dc:subject>^d4419</dc:subject>
<dc:type>article</dc:type>
<dc:date>200510</dc:date>
</metadata>
</record>
</ibecs-document>
